NetworkNewsBreaks

FridayJul 05, 2019 1:37 pm

NetworkNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) Dominates California Edibles Market

San Mateo, California-based Plus Products (CSE: PLUS) (OTCQB: PLPRF) has emerged as a market leader in its home state since its introduction in 2015, quickly becoming the No. 1 best-selling, cannabis-infused edibles brand in California (http://nnw.fm/HcHs2). A recent article discussing the company reads, “Plus Products has found a way into the hearts of residents in the Golden State, no doubt because its hugely popular cannabis-infused gummies and mints have found favor with their palates. The latest rankings compiled by data intelligence analyst Headset from retail sales data show the company’s products placing in the tenth, ninth, sixth, second and first…

Continue Reading

FridayJul 05, 2019 11:57 am

NetworkNewsBreaks – Fortune Business Insights Issues Detailed Research Report on the Push-to-Talk Industry

Fortune Business Insights, a provider of meticulous analysis with a specialized focus on accuracy of data obtained, recently published a report including a market forecast, analysis and insight on the global push-to-talk (“PTT”) market. As technology continues to advance, PTT solutions are transforming to be more efficient. Through the deployment of enhanced internet services, major telecommunications companies such as AT&T Inc. (NYSE: T), Motorola Solutions Inc. (NYSE: MSI) and Sprint Corporation (NYSE: S) are working to deliver prompt and accurate voice processing systems. According to the report, AT&T intends to develop new PTT devices for mission-critical push-to-talk (“MCPTT”) that reach…

Continue Reading

FridayJul 05, 2019 10:39 am

NetworkNewsBreaks – ROTH Capital Partners to Host RNA Revolution Conference in New York City

Full-service investment bank ROTH Capital Partners recently announced that it will host its RNA Revolution Conference at the 1 Hotel Central Park in New York City on Wednesday, July 17, 2019. According to the update, the invitation-only event for ROTH institutional clients will provide investors the opportunity to deep dive into scientific discussions about differences between various RNA modalities (mRNA, ASO, siRNA, and RNA-targeted small molecule), drug delivery nuances, and improvements to these drugs to make them more effective and safer. Co-Head of Biotechnology Research and Senior Research Analyst Yasmeen Rahimi, Ph.D. will moderate four panel discussions addressing topics on…

Continue Reading

FridayJul 05, 2019 10:11 am

NetworkNewsBreaks – ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) Closes $15.6M Underwritten Public Offering

ContraVir Pharmaceuticals (NASDAQ: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, has closed an underwritten public offering resulting in total gross proceeds of approximately $15.6 million. According to the update, the offered securities included (i) Class A units, at a combined price of $6.00 per unit, each consisting of one share of common stock and one warrant to purchase one share of common stock, and (ii) Class B units, at a combined price of $1,000 per unit, each consisting of one share…

Continue Reading

FridayJul 05, 2019 9:39 am

NetworkNewsBreaks – Akero Therapeutics, Inc. (NASDAQ: AKRO) Closes $105.8 Million IPO

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (“NASH”) and other serious metabolic disorders, has closed its initial public offering, resulting in gross proceeds of approximately $105.8 million. The offering of 6,612,500 shares included 862,500 additional shares per the full exercise of the over-allotment option granted to the underwriters. The shares, sold each at the public offering price of $16.00, began trading on the Nasdaq Global Select Market on June 20, 2019 under the ticker symbol "AKRO." ROTH Capital Partners acted as lead manager for the offering. To view the full press…

Continue Reading

FridayJul 05, 2019 9:19 am

NetworkNewsBreaks – ArQule, Inc. (NASDAQ: ARQL) Closes $103.7M Follow-On

ArQule (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, recently closed its underwritten public offering of 10,637,500 shares of common stock, which includes 1,387,500 shares representing the over-allotment option that the underwriters fully exercised. With shares sold at the public offering price of $9.75 each, the offering resulted in gross proceeds of roughly $103.7 million. The company plans to use the proceeds toward its clinical programs and for general corporate purposes. ROTH Capital Partners acted as co-manager for the offering. To view the full press release, visit http://nnw.fm/kFr9H…

Continue Reading

WednesdayJul 03, 2019 12:46 pm

NetworkNewsBreaks – Buzzfeed.com Features Wildflower Brands Inc.’s (CSE: SUN) (OTCQB: WLDFF) Disposable Vaporizers, Aches and Immunity

Vancouver-based company Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was recently featured alongside various cannabis companies including Burkelman, Vertly and Cannuka in an article on Buzzfeed.com titled, ‘Here's Why You Should Buy CBD For Everyone You Know This Holiday’ authored by Jessica Probus. Wildflower’s CBD Disposable Vaporizer Pen contains a total of 150mg of CBD. The company’s CBD+ VAPORIZER – Immunity also includes eucalyptus, thyme and myrrh to boost the immune system and provide a smooth refreshing draw. Wildflower's CBD+ VAPORIZER – Aches provides fast acting pain relief by reducing inflammation using a mixture of CBD, peppermint, spearmint and lavender. To…

Continue Reading

WednesdayJul 03, 2019 12:25 pm

NetworkNewsBreaks – Fortune Business Insights Provides Detailed Analysis on the Offshore Wind Power Industry

Fortune Business Insights, a provider of meticulous analysis with a specialized focus on accuracy of data obtained, recently published a report including a market forecast, analysis and insight on the global offshore wind power market. As economic demands and popularity increase in offshore wind power the United Kingdom and China are expected to lead the global market, with the demand of energy consumption increasing and resources continue to decrease in the forecasted reporting years. In terms of water depth, shallow levels under 30 meters (“M”) are currently leading in the market due to the ease of technological access. While current…

Continue Reading

WednesdayJul 03, 2019 11:10 am

NetworkNewsBreaks – Wuhan General Group (China) Inc. (WUHN) Issues Update on Third Quarter Corporate Highlights

Wuhan General Group (China) Inc. (OTC: WUHN) on Tuesday issued a statement to shareholders and provided a list of its corporate milestones. In the update, the company clarified that Wuhan General Group is a U.S.-registered corporation and has no dealings with any Chinese parties relating to its ongoing business activities. The company has retained the services of a law firm in order to take all necessary steps to file a name change with FINRA to remove any possible confusion with its current name and to better reflect the nature of the business. In addition, the company announced that it is…

Continue Reading

WednesdayJul 03, 2019 10:59 am

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maxim Group’s Conference on Alzheimer’s Disease

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. According to the update, Tesi’s presentation addressed how INmune Bio’s XPro1595 drug candidate targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. “I was delighted to showcase INmune Bio’s development program with XPro1595 in Alzheimer’s disease,” Tesi said in the news release. “We believe…

Continue Reading